To standardize and guide the implementation of  clinical  trials  of  recombinant  human coagulation factor VIII and IX products, and promote the virtuous development of such products, NMPA organized the formulation of the Technical  Guidelines  for  Clinical Trial of Recombinant Human Coagulation Factor  VIII  and  the  Technical  Guidelines for  Clinical  Trial  of  Recombinant  Human Coagulation Factor IX, which were issued on June 11, 2019.